Expression was assessed under basal conditions and following mebendazole exposure (0.7 μM).<h4>Results</h4>Basal expression revealed elevated ENOX2 and MMP2 in aggressive cancers (MDA-MB-231, PANC1). Here, ENOX2 is linked to cancer.